肿瘤细胞治疗研究
ALL SOURCES
Immune Absence as a Proposed Framework for Delayed Relapse After Curative-Intent Treatment in Human Papillomavirus-Associated Cervical Cancer.
在HPV相关宫颈癌中，根治性治疗后延迟复发仍然难以解释和预测，包括在持续缓解且循环肿瘤DNA（ctDNA）或循环HPV DNA检测不到的时期之后。
Immune cell densities, HLA status, and PD-L1 expression in stage I neuroendocrine neoplasm of the uterine cervix.
仅3例为纯NENs，而13例包含腺癌或鳞状细胞癌成分。
Ligand-Based CAR-T Cells Targeting EGFR Exhibit Favorable Antitumor Effects Against Gynecologic Malignancies.
基于配体的 EGFR CAR-T 细胞可能成为多种妇科恶性肿瘤的有前景疗法。
Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
鉴于ICI诱导的CRS是一种罕见但严重的并发症，应监测ICI给药后出现的发热及其他全身性状况。
Trop-2 expression and the tumor immune microenvironment in cervical cancer.
宫颈癌中Trop-2的表达与瘤内TILs水平升高相关，提示Trop-2靶向治疗单独或联合免疫检查点抑制剂具有潜在应用价值。
Protease-Activated Receptor 1 (PAR1) Expression Contributes to HPV-Associated Oropharyngeal Cancer Prognosis.
我们的结果表明，PAR1表达影响HPV相关口咽癌的预后和复发率。
Association between Tumor Mutational Burden, Stromal CD8(+) Tumor-Infiltrating Lymphocytes, and Clinical Factors in Cervical Cancers Treated with Radi
这些数据表明TMB与CD8+ TIL密度的独立性，以及ARID1A改变参与接受放疗的宫颈癌患者的抗肿瘤免疫反应，值得进一步的机制研究和前瞻性验证。
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
